278 related articles for article (PubMed ID: 31364160)
1. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
Bal S; Weaver A; Cornell RF; Costa LJ
Br J Haematol; 2019 Sep; 186(6):807-819. PubMed ID: 31364160
[TBL] [Abstract][Full Text] [Related]
2. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
4. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
5. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.
Soh KT; Wallace PK
Curr Protoc Cytom; 2019 Sep; 90(1):. PubMed ID: 31608132
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
12. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
13. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
14. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
15. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
16. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
[TBL] [Abstract][Full Text] [Related]
18. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
Cho H; Shin S; Chung H; Jang JE; Kim YR; Cheong JW; Min YH; Lee ST; Choi JR; Kim JS
Br J Haematol; 2022 Aug; 198(3):503-514. PubMed ID: 35505579
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease analysis in myeloma - when, why and where.
Yanamandra U; Kumar SK
Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease testing after stem cell transplantation for multiple myeloma.
Sherrod AM; Hari P; Mosse CA; Walker RC; Cornell RF
Bone Marrow Transplant; 2016 Jan; 51(1):2-12. PubMed ID: 26191950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
